MAP1LC3A and metabolic dysfunction-associated steatohepatitis: In vitro evaluation additionally printed that the expression of LC3 and NRLP3 as decided by using immunofluorescence used to be altered utilizing the miR-375-3p inhibitor, whereas ATG2B-LV restored the expression of LC3 and NRLP3 proteins in the FFA-induced NASH cell-like model (Fig. 4G).